ALEC - Alector, Inc.
IEX Last Trade
1.86
-2.100 -112.903%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:58 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$3.96
-2.10
-53.03%
Fundamental analysis
25%
Profitability
25%
Dept financing
19%
Liquidity
67%
Performance
16%
Performance
5 Days
-0.54%
1 Month
-53.28%
3 Months
-62.47%
6 Months
-57.57%
1 Year
-76.90%
2 Year
-79.07%
Key data
Stock price
$1.86
DAY RANGE
$1.88 - $3.96
52 WEEK RANGE
$1.86 - $8.90
52 WEEK CHANGE
-$76.73
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Arnon Rosenthal
Region: US
Website: alector.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alector.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.
Recent news